MEDU-47. PEROXIREDOXIN1 IS A THERAPEUTIC TARGET IN GROUP-3 MEDULLOBLASTOMAS

Group-3 Medulloblastomas (MBL) has the worst prognosis due to its resistance to radiation and chemotherapy with a 5-year survival of 30%. Thus, there is an urgent need to elucidate targets that can sensitize Group-3 tumors to conventional treatments. We identified PRDX1 as a candidate therapeutic ta...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neuro Oncol
Autors principals: Sajesh, Babu, Omar, Refaat, Jarmasz, Jessica, Stirton, Hannah, Morrison, Ludivine, Wang, W, Pu, J, Sun, HD, Bigio, Marc Del, Werbowetski-Ogilvie, Tamra, Wolfl, Matthais, Remke, Marc, Taylor, Michael, Eberhart, Charles, Symons, Marc, Ruggieri, Rosamaria, Vanan, Magimairajan Issai
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2017
Matèries:
Abstracts
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5475172/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox083.196
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars